Abstract
In recent years, increasing attention has been paid to bioengineered bacteria as vectors for the treatment of allergic diseases. The methods for preparing bioengineered bacteria that can express exogenous genes are improving. Research has focused mainly on application of bioengineered bacteria expressing recombinant allergens, hypoallergenic derivatives of allergens, T-cell epitope derivatives, cytokines, or as mucosal adjuvants to enhance immunotherapy effects. This strategy offers new ideas for the treatment of allergic diseases. This review summarizes recent advances in use of live bioengineered bacteria in allergic diseases as well as the challenges of using microorganisms (or their components) in immunotherapy.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
